

# BC Cancer Protocol Summary for Treatment of Metastatic Pancreatic or Biliary Tract Cancer using Irinotecan, Fluorouracil and Leucovorin

**Protocol Code**

**GIPAVFFIRI**

**Tumour Group**

**Gastrointestinal**

**Contact Physician**

**GI Systemic Therapy**

## ELIGIBILITY:

### Patients must have:

- Locally advanced unresectable or metastatic pancreatic adenocarcinoma, or biliary tract (cholangiocarcinoma or gallbladder) cancer, and
- Previously received one or two prior lines of treatment in advanced setting

### Patients should have:

- ECOG performance status less than or equal to 2

**Note:** Consideration of oxaliplatin-based therapy (GIPAVFFOX) should be given for those patients who have Gilbert's Syndrome or who may be compromised by potential irinotecan toxicities.

## CAUTIONS:

- Adequate marrow reserve, renal and liver function
- Patients with recent myocardial infarction, uncontrolled angina, hypertension, cardiac arrhythmias, congestive heart failure or other serious medical illness
- Patients with baseline greater than 3 loose BM per day
- Patients with baseline hyperbilirubinemia (greater than 26 micromol/L) not explained by degree of liver metastases

## TESTS:

- Baseline: CBC & Diff, creatinine, total bilirubin, ALT, alkaline phosphatase, albumin, sodium, potassium, random glucose, HbA1c, DPYD test (not required if previously tested, or tolerated fluorouracil or capecitabine)
- Baseline if clinically indicated: CEA, CA 19-9, GGT, ECG
- Prior to each cycle: CBC & Diff, creatinine, total bilirubin, ALT
- If clinically indicated: CEA, CA 19-9, alkaline phosphatase, albumin, GGT, sodium, potassium, random glucose, HbA1c, ECG
- For patients on warfarin, weekly INR during fluorouracil therapy until stable warfarin dose established, then INR prior to each cycle

## PREMEDICATIONS:

- Antiemetic protocol for moderate emetogenic chemotherapy (see [SCNAUSEA](#))
- Atropine may be required for treatment or prophylaxis of diarrhea (see precautions)
- Prochlorperazine should be avoided on the same day as irinotecan treatment due to the increased incidence of akathisia

## TREATMENT:

A cycle equals:

Drug	Dose	BC Cancer Administration Guidelines
irinotecan	180 mg/m <sup>2</sup>	IV in 500 mL D5W over 1 hour 30 min*
leucovorin <sup>†</sup>	400 mg/m <sup>2</sup>	IV in 250 mL D5W over 1 hour 30 min*
fluorouracil <sup>†</sup>	400 mg/m <sup>2</sup>	IV push
fluorouracil	2400 mg/m <sup>2</sup>	IV over 46 h in D5W to a total volume of 230 mL by continuous infusion at 5 mL/h via Baxter LV5 INFUSOR **

Repeat every 14 days until progression.

\* Irinotecan and leucovorin may be infused at the same time by using a y-connector placed immediately before the injection site. Irinotecan and leucovorin should not be combined in the same infusion bag.

<sup>†</sup> fluorouracil IV push is optional in the advanced setting:

fluorouracil IV push	leucovorin administration options
fluorouracil IV push given	<ul style="list-style-type: none"><li>• leucovorin given as IV infusion OR</li><li>• leucovorin given as 20 mg/m<sup>2</sup> IV push</li></ul>
fluorouracil IV push omitted	<ul style="list-style-type: none"><li>• leucovorin omitted OR</li><li>• leucovorin given as IV infusion OR</li><li>• leucovorin given as 20 mg/m<sup>2</sup> IV push</li></ul>

\*\* Alternative administration:

- For 3000 to 5500 mg dose **select INFUSOR per dose range below (doses outside dose banding range are prepared as ordered):**

▪

Dose Banding Range	Dose Band INFUSOR (mg)
Less than 3000 mg	Pharmacy to mix specific dose
3000 to 3400 mg	3200 mg
3401 to 3800 mg	3600 mg
3801 to 4200 mg	4000 mg
4201 to 4600 mg	4400 mg
4601 to 5000 mg	4800 mg
5001 to 5500 mg	5250 mg
Greater than 5500 mg	Pharmacy to mix specific dose

- Inpatients: 1200 mg/m<sup>2</sup>/day in 1000 mL D5W by continuous infusion daily over 23 h for 2 days

Patients with PICC lines should have a weekly assessment of the PICC site for evidence of infection or thrombosis.

All patients should be advised to obtain an adequate supply of loperamide (IMODIUM®) with directions for the management of diarrhea.

## DOSE MODIFICATIONS:

### Fluorouracil Dosing Based on DPYD Activity Score (DPYD-AS)

Refer to "Fluorouracil and Capecitabine Dosing Based on DPYD Activity Score (DPYD-AS)" on [www.bccancer.bc.ca/health-professionals/clinical-resources/cancer-drug-manual](http://www.bccancer.bc.ca/health-professionals/clinical-resources/cancer-drug-manual).

## Dose Levels for Toxicities

Agent	Dose Level 0 (Starting Dose)	Dose Level –1	Dose Level –2	Dose Level –3
irinotecan	180 mg/m <sup>2</sup>	150 mg/m <sup>2</sup>	120 mg/m <sup>2</sup>	Discontinue Therapy
leucovorin	<p><b>No dose modifications.</b></p> <ul style="list-style-type: none"> <li>If fluorouracil push is omitted, leucovorin may also be omitted or given as 20 mg/m<sup>2</sup> IV push</li> <li>If irinotecan is omitted, leucovorin may be given as 20 mg/m<sup>2</sup> IV push</li> </ul>			
fluorouracil push	400 mg/m <sup>2</sup>	320 mg/m <sup>2</sup>	240 mg/m <sup>2</sup>	Discontinue Therapy
fluorouracil infusion	2400 mg/m <sup>2</sup>	2000 mg/m <sup>2</sup>	1600 mg/m <sup>2</sup>	Discontinue Therapy

## A. Dose Modifications for HEMATOLOGIC Toxicity

Prior to a Cycle (Day 1)	Toxicity		Dose Level For Subsequent Cycles	
	Grade	ANC (x10 <sup>9</sup> /L)	irinotecan	fluorouracil
<ul style="list-style-type: none"> <li>If ANC less than 1.5 on Day 1 of cycle, hold treatment. Perform weekly CBC, maximum of 2 times.</li> <li>If ANC is greater than or equal to 1.5 within 2 weeks, proceed with treatment at the dose level noted across from the <b>lowest ANC</b> result of the delayed week(s).</li> <li>If ANC remains less than 1.5 after 2 weeks, discontinue treatment.</li> </ul>	1	Greater than or equal to 1.5	Maintain dose level	Maintain dose level
	2	1.0 to less than 1.5	Maintain dose level	Maintain dose level
	3	0.5 to less than 1.0	↓ 1 dose level	↓ 1 dose level
	4	less than 0.5	↓ 2 dose levels	↓ 2 dose levels
	<b>Grade 4 neutropenia &amp; greater than or equal to Grade 2 fever</b>		↓ 2 dose levels	↓ 2 dose levels

Prior to a Cycle (Day 1)	Toxicity		Dose Level For Subsequent Cycles	
	Grade	Platelets (x10 <sup>9</sup> /L)	irinotecan	fluorouracil
<ul style="list-style-type: none"> <li>▪ If platelets less than 75 on Day 1 of cycle, hold treatment. Perform weekly CBC, maximum of 2 times.</li> <li>▪ If platelets greater than or equal to 75 within 2 weeks, proceed with treatment at the dose level noted across from the <b>lowest platelets</b> result of the delayed week(s).</li> <li>▪ If platelets remain less than 75 after 2 weeks, discontinue treatment.</li> </ul>	1	Greater than or equal to 75	Maintain dose level	Maintain dose level
	2	50 to less than 75	Maintain dose level	Maintain dose level
	3	10 to less than 50	↓ 1 dose level	↓ 1 dose level
	4	Less than 10	↓ 2 dose levels	↓ 2 dose levels

## B. Dose Modifications for NON-HEMATOLOGIC Toxicity

Prior to a Cycle (Day 1)	Toxicity		Dose Level For Subsequent Cycles	
	Grade	Diarrhea	irinotecan	fluorouracil
<ul style="list-style-type: none"> <li>If diarrhea greater than or equal to Grade 2 on Day 1 of any cycle, hold treatment. Perform weekly checks, maximum 2 times.</li> <li>If diarrhea is less than Grade 2 within 2 weeks, proceed with treatment at the dose level noted across from the <b>highest</b> Grade experienced.</li> <li>If diarrhea remains greater than or equal to Grade 2 after 2 weeks, discontinue treatment.</li> </ul>	1	Increase of 2 to 3 stools/day, or mild increase in loose watery colostomy output	Maintain dose level	Maintain dose level
	2	Increase of 4 to 6 stools, or nocturnal stools or mild increase in loose watery colostomy output	Maintain dose level	Maintain dose level
	3	Increase of 7 to 9 stools/day or incontinence, malabsorption; or severe increase in loose watery colostomy output	↓ 1 dose level	↓ 1 dose level
	4	Increase of 10 or more stools/day or grossly bloody colostomy output or loose watery colostomy output requiring parenteral support; dehydration	↓ 2 dose levels	↓ 2 dose levels

Prior to a Cycle (Day 1)	Toxicity		Dose Level For Subsequent Cycles	
	Grade	Stomatitis	irinotecan	fluorouracil
<ul style="list-style-type: none"> <li>If stomatitis greater than or equal to Grade 2 on Day 1 of any cycle, hold treatment. Perform weekly checks, maximum 2 times.</li> <li>If stomatitis is less than Grade 2 within 2 weeks, proceed with treatment at the dose level noted across from the <b>highest</b> Grade experienced.</li> <li>If stomatitis remains greater than or equal to Grade 2 after 2 weeks, discontinue treatment.</li> </ul>	1	Painless ulcers, erythema or mild soreness	Maintain dose level	Maintain dose level
	2	Painful erythema, edema, or ulcers but can eat	Maintain dose level	Maintain dose level
	3	Painful erythema, edema, ulcers, and cannot eat	Maintain dose level	↓ 1 dose level
	4	As above but mucosal necrosis and/or requires enteral support, dehydration	Maintain dose level	↓ 2 dose levels

## PRECAUTIONS:

- Diarrhea:** may be life threatening and requires prompt, aggressive treatment.
  - Early diarrhea** or abdominal cramps occurring within the first 24 hours is treated with **atropine** 0.3 mg **subcutaneously**. **Dose may be repeated every 30 minutes as needed to a maximum of 1.2 mg.** Prophylactic atropine may be required for subsequent treatments.
  - Late diarrhea** has an onset of 5 to 11 days post-treatment, a duration of 3 to 7 days and must be treated promptly with **loperamide** (eg, IMODIUM®). The loperamide dose is higher than recommended by the manufacturer. Instruct patient to have loperamide on hand and start treatment at the first poorly formed or loose stool, or earliest onset of more frequent stool than usual:
    - 4 mg stat**
    - then 2 mg every 2 hours until diarrhea-free for 12 hours**
    - may take 4 mg every 4 hours at night
  - The use of drinks such as GATORADE® or POWERADE® to replace fluid & body salts is recommended.
  - Consideration should be given to the use of an oral fluoroquinolone (e.g., ciprofloxacin) in patients with persistent diarrhea despite adequate loperamide or if a fever develops in the setting of diarrhea, even without neutropenia. If diarrhea persists for longer than 48 hours then hospitalization for parenteral hydration should be considered.
- Other cholinergic symptoms:** may occur during or shortly after infusion of irinotecan including rhinorrhea, increased salivation, lacrimation, diaphoresis and flushing. These should be treated with atropine 0.3 mg **subcutaneously**. **Dose may be repeated every 30 minutes as needed to a maximum of 1.2 mg.** Prophylactic atropine may be required for subsequent treatments.

3. **Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated aggressively.
4. **Gilbert's syndrome:** Increases the risk of irinotecan-induced toxicity. A screen for Gilbert's Syndrome using direct/indirect serum bilirubin is recommended.
5. **Hepatic dysfunction:** Irinotecan has not been studied in patients with bilirubin greater than 35 micromol/L or ALT greater than 3x the upper limit of normal if no liver metastases, or ALT greater than 5x the upper limit of normal with liver metastases. The risk of severe neutropenia may be increased in patients with a serum bilirubin of 17 to 35 micromol/L.
6. **Pulmonary toxicity:** Severe pulmonary toxicity consisting of dyspnea, fever and reticulonodular pattern on chest x-ray has been reported rarely. Supportive care is required.
7. **Prior pelvic radiotherapy** or radiotherapy to greater than 15% of the bone marrow bearing area may increase the degree of myelosuppression associated with this regimen, and caution is recommended in these cases. Close monitoring of the CBC is essential.
8. **Stomatitis:** Sucking ice chips may be considered for patients experiencing stomatitis. Remove dentures and place ice chips in mouth five minutes before chemotherapy. Continuously swish in mouth for 30 minutes, replenishing as ice melts. This may cause numbness or headaches, which subside quickly.
9. **Myocardial** ischemia and angina occurs rarely in patients receiving fluorouracil or capecitabine. Development of cardiac symptoms including signs suggestive of ischemia or of cardiac arrhythmia is an indication to discontinue treatment. If there is development of cardiac symptoms patients should have urgent cardiac assessment. Generally re-challenge with either fluorouracil or capecitabine is not recommended as symptoms potentially have a high likelihood of recurrence which can be severe or even fatal. Seeking opinion from cardiologists and oncologists with expert knowledge about fluorouracil / capecitabine toxicity is strongly advised under these circumstances. The toxicity should also be noted in the patient's allergy profile.
10. **Dihydropyrimidine dehydrogenase (DPD) deficiency** may result in severe and unexpected toxicity – stomatitis, diarrhea, neutropenia, neurotoxicity – secondary to reduced drug metabolism. This deficiency is thought to be present in about 3% of the population.
11. **Potential Drug Interactions:** Anticonvulsants and other drugs which induce Cytochrome P450 3A4 isoenzyme activity e.g. carbamazepine, phenytoin and St John's Wort may decrease the therapeutic and toxic effects of irinotecan. Prochlorperazine may increase the incidence of akathisia and should be avoided on the day of irinotecan treatment.
12. **Possible drug interaction with fluorouracil and warfarin** has been reported and may occur at any time. For patients on warfarin, weekly INR during fluorouracil therapy is recommended until a stable warfarin dose is established. Thereafter, INR prior to each cycle. Consultation to cardiology/internal medicine should be considered if difficulty in establishing a stable warfarin dose is encountered. Upon discontinuation of fluorouracil, repeat INR weekly for one month.
13. **Possible drug interaction with fluorouracil and phenytoin and fosphenytoin** has been reported and may occur at any time. Close monitoring is recommended. Fluorouracil may increase the serum concentration of these two agents.

**Call the GI Systemic Therapy physician at your regional cancer centre or the GI Systemic Therapy Chair Dr. Theresa Chan at (604) 930-2098 with any problems or questions regarding this treatment program.**



**References :**

1. Wang-Gillam A, Li C, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomized, open-label, phase 3 trial. *Lancet* 2016; 387:545-557.
2. Peng C, Saffo S, Shusterman M, et al. Analysis of the Impact of Eliminating Bolus 5-fluorouracil in Metastatic Colorectal Cancer. *J Clin Onc*. 2023 Feb 1;41 (4): Suppl.59
3. Peng C, Saffo S, Oberstein PE, et al. Omission of 5-Fluorouracil Bolus From Multidrug Regimens for Advanced Gastrointestinal Cancers: A Multicenter Cohort Study. *J Natl Compr Canc Netw*. 2024 Sep 5;22(8):521-527.